This is thanks to Lilly's dominance in the billion-dollar weight loss drug market. Lilly's Mounjaro and Zepbound have helped ...

Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...

Eli Lilly(NYSE:LLY) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights ...

Shares of Eli Lilly & Co. LLY slipped 1.88% to $906.18 Tuesday, on what proved to be an all-around mixed trading session for ...

Eli Lilly said on Friday the U.S. Food and Drug Administration approved its eczema drug for use in adults and children above ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Eli Lilly (LLY) stock gained as Citi resumed its covderage with a buy rating and $1,060 price target, citing optimism for its ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 586.36% and ...

Eli Lilly is investing $1.8 billion across two manufacturing sites in Ireland to boost production of its hugely popular ...

Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Eli Lilly with a target price of $1100 ...

Tandem Diabetes Care (Nasdaq:TNDM) announced today that it received clearance for the use of rapid-acting insulin with its ...

Sold under the brand names Mounjaro and Zepbound, tirzepatide has been an incredible growth driver for Eli Lilly. In 2022 -- ...